Cancel
Clay Siegall
President & Chief Executive Officer
@
Immunome
z9b9jj2p@prxywwtj.6zj
Sign up to see email
Known information
- Previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997
- Under his leadership, Seagen became the world leader in ADC therapeutics, earned FDA approvals for four cancer therapies, and grew to over $2 billion in annual revenue
- Raised well over $1 billion of financing for Seagen from public and private markets
- Oversaw the company’s acquisition of Cascadian Therapeutics
- Worked in positions of increasing responsibilities at Bristol Myers Squibb and previously at the National Cancer Institute
- Earned a PhD in Genetics at George Washington University
- Holds a B.S. in Zoology from the University of Maryland
About Immunome
Immunome is a biotechnology company focused on developing innovative cancer therapies, including immunotherapies and targeted treatments, using its proprietary memory B cell hybridoma technology.
Report inaccurate information
